London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami
Image Source: AsiaOne
London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami GlobeNewswire April 15, 2024 LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), highlighting its safety, efficacy, bioavailability, and predictable PK parameters. CBDS maintains improved oral formulation capabilities vs cannabidiol, including tablet and water-based solutions.
Source: AsiaOne
Breaking! Business News
Nature’s Sunshine Recognized with Six Stevie Awards in the 2024 American Business AwardsNature’s Sunshine Recognized with Six Stevie Awards in the 2024 American Business Awards ...
Read More
EB5 Capital Litigates USCIS’ Recent EB-5 Filing Fee IncreasesEB5 Capital Litigates USCIS’ Recent EB-5 Filing Fee Increases GlobeNewswire ...
Read More
With a team of skilled butchers on staff, Bagley Farms Meat Market offers a personalized meat shoppi...
Read More
The Law Office of Jason B. Going is located in Belleville, IL. It helps clients in various legal mat...
Read More
Keep Dry Roofing LLC is a BBB-accredited roofing service in Maryland Heights, providing around-the-c...
Read More
Star Evaluator emerges as a trusted platform, revolutionizing online reviews with its commitment to ...
Read More
WebForce has enabled partnering supplement businesses to enjoy massive growth through its award-winn...
Read More
EnviroGold Global Launches Private Placement and Announces Engagement with Sequoia Corporate Finance Pty LtdEnviroGold Global Launches Private Placement and Announces Engagement with Sequoia Corporate Finance...
Read More